GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » China Medical System Holdings Ltd (HKSE:00867) » Definitions » Debt-to-Revenue

China Medical System Holdings (HKSE:00867) Debt-to-Revenue : 0.19 (As of Dec. 2023)


View and export this data going back to 2010. Start your Free Trial

What is China Medical System Holdings Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

China Medical System Holdings's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was HK$1,406 Mil. China Medical System Holdings's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was HK$18 Mil. China Medical System Holdings's annualized Revenue for the quarter that ended in Dec. 2023 was HK$7,445 Mil. China Medical System Holdings's annualized Debt-to-Revenue for the quarter that ended in Dec. 2023 was 0.19.


China Medical System Holdings Debt-to-Revenue Historical Data

The historical data trend for China Medical System Holdings's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

China Medical System Holdings Debt-to-Revenue Chart

China Medical System Holdings Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.12 0.09 0.21 0.20 0.16

China Medical System Holdings Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.19 0.20 0.19 0.14 0.19

Competitive Comparison of China Medical System Holdings's Debt-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, China Medical System Holdings's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


China Medical System Holdings's Debt-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, China Medical System Holdings's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where China Medical System Holdings's Debt-to-Revenue falls into.



China Medical System Holdings Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

China Medical System Holdings's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(1405.578 + 18.234) / 8764.762
=0.16

China Medical System Holdings's annualized Debt-to-Revenue for the quarter that ended in Dec. 2023 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(1405.578 + 18.234) / 7444.604
=0.19

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is two times the quarterly (Dec. 2023) Revenue data.


China Medical System Holdings Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of China Medical System Holdings's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


China Medical System Holdings (HKSE:00867) Business Description

Traded in Other Exchanges
Address
510 King’s Road, Unit 2106, 21st Floor, North Point, Island Place Tower, Hong Kong, HKG
China Medical System Holdings Ltd is active in the healthcare segment. It is one of the leading China-based pharmaceutical services companies in the country. The company's business mainly involves the marketing, promotion, and sales of prescription pharmaceutical products manufactured by domestic pharmaceutical companies. Some of its products include Plendil; Salofalk; Combizym; Ganfule Capsules; Xidakang; Hirudoid; and others. Geographically, it derives revenue from China.
Executives
Treasure Sea Limited 2101 Beneficial owner
Lam Kong 2201 Interest of corporation controlled by you

China Medical System Holdings (HKSE:00867) Headlines

No Headlines